-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Establishment Labs (NASDAQ:ESTA) Sees Strong Trading Volume
Establishment Labs (NASDAQ:ESTA) Sees Strong Trading Volume
Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) shares saw unusually-high trading volume on Friday . Approximately 2,506 shares were traded during mid-day trading, a decline of 98% from the previous session's volume of 126,123 shares.The stock last traded at $66.60 and had previously closed at $65.69.
Analysts Set New Price Targets
Several equities research analysts have commented on ESTA shares. Stephens lowered their price target on shares of Establishment Labs from $90.00 to $87.00 and set an "overweight" rating on the stock in a report on Wednesday, December 28th. BTIG Research upped their price target on shares of Establishment Labs from $90.00 to $100.00 and gave the company a "buy" rating in a report on Friday, October 7th. Finally, Mizuho started coverage on shares of Establishment Labs in a report on Wednesday, October 12th. They issued a "buy" rating and a $70.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Establishment Labs presently has an average rating of "Moderate Buy" and a consensus price target of $97.00.
Get Establishment Labs alerts:Establishment Labs Stock Performance
The firm's 50 day moving average price is $65.34 and its 200-day moving average price is $60.84. The company has a debt-to-equity ratio of 97.56, a quick ratio of 3.29 and a current ratio of 4.27. The firm has a market capitalization of $1.67 billion, a PE ratio of -22.10 and a beta of 1.06.
Establishment Labs (NASDAQ:ESTA – Get Rating) last posted its earnings results on Monday, November 7th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.27). Establishment Labs had a negative return on equity of 209.77% and a negative net margin of 49.50%. The firm had revenue of $38.25 million for the quarter, compared to analysts' expectations of $37.55 million. During the same period in the previous year, the company earned ($0.61) earnings per share. On average, research analysts expect that Establishment Labs Holdings Inc. will post -2.6 EPS for the current year.Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its position in shares of Establishment Labs by 3,244.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company's stock worth $41,000 after purchasing an additional 584 shares during the last quarter. Lazard Asset Management LLC raised its position in shares of Establishment Labs by 104.5% during the 1st quarter. Lazard Asset Management LLC now owns 963 shares of the company's stock worth $64,000 after purchasing an additional 492 shares during the last quarter. BNP Paribas Arbitrage SNC raised its holdings in Establishment Labs by 100.6% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 1,689 shares of the company's stock valued at $92,000 after acquiring an additional 847 shares during the last quarter. Bank of America Corp DE raised its holdings in Establishment Labs by 38.4% in the 1st quarter. Bank of America Corp DE now owns 2,227 shares of the company's stock valued at $150,000 after acquiring an additional 618 shares during the last quarter. Finally, Twin Lakes Capital Management LLC acquired a new stake in Establishment Labs in the 3rd quarter valued at about $163,000. Institutional investors and hedge funds own 75.26% of the company's stock.
Establishment Labs Company Profile
(Get Rating)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
Further Reading
- Get a free copy of the StockNews.com research report on Establishment Labs (ESTA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
成立实验室控股公司(纳斯达克代码:ESTA-GET Rating)的股票周五成交量异常高。午盘成交量约为2,506股,较前一交易日的126,123股减少98%。该股最新报66.60美元,此前收盘报65.69美元。
分析师设定新的价格目标
几位股票研究分析师对ESTA的股票发表了评论。斯蒂芬斯在12月28日(星期三)的一份报告中将机构实验室的股票目标价从90.00美元下调至87.00美元,并对该股设定了“增持”评级。BTIG Research在10月7日星期五的一份报告中将建立实验室的股票目标价从90美元上调至100.00美元,并给予该公司“买入”评级。最后,瑞穗在10月12日星期三的一份报告中开始报道机构实验室的股票。他们对该股的评级为买入,目标价为70.00美元。一位研究分析师对该股的评级为持有,四位分析师对该股的评级为买入。根据MarketBeat.com的数据,建立实验室目前的平均评级为“适度买入”,共识目标价为97.00美元。
到达建立实验室警报:机构实验室股票表现
该公司的50日移动均线价格为65.34美元,200日移动均线价格为60.84美元。该公司的负债权益比率为97.56,速动比率为3.29,流动比率为4.27。该公司的市值为16.7亿美元,市盈率为-22.10,贝塔系数为1.06。
成立实验室(纳斯达克代码:ESTA-GET Rating)最近一次公布收益结果是在11月7日星期一。该公司公布该季度每股收益(EPS)为0.76美元,低于市场普遍预期的0.49美元和0.27美元。成立实验室的净资产回报率为负209.77%,净利润率为负49.50%。该公司当季营收为3,825万美元,高于分析师预期的3,755万美元。去年同期,该公司每股收益为0.61美元。研究分析师平均预计,机构实验室控股公司本年度每股收益将达到2.6欧元。机构资金流入和流出
对冲基金最近调整了对该股的持有量。法国巴黎银行套利公司在第一季度将其在建立实验室的股票头寸增加了3,244.4%。法国巴黎银行套利公司现在持有602股该公司股票,价值41,000美元,在上个季度又购买了584股。Lazard Asset Management LLC在第一季度将其在机构实验室的持股比例提高了104.5%。Lazard Asset Management LLC在上个季度又购买了492股,现在拥有963股该公司股票,价值6.4万美元。法国巴黎银行套利SNC在第三季度增持了100.6%的机构实验室股份。法国巴黎银行套利SNC现在拥有1,689股该公司股票,价值92,000美元,在上个季度额外购买了847股。美国银行DE在第一季度增持了38.4%的机构实验室股份。美国银行DE目前持有2,227股该公司股票,价值15万美元,此前该公司在上一季度增持了618股。最后,双湖资本管理有限责任公司在第三季度收购了建立实验室的新股份,价值约16.3万美元。机构投资者和对冲基金持有该公司75.26%的股票。
建立实验室公司简介
(获取评级)
建立实验室控股公司是一家医疗技术公司,生产和营销用于美容和重建整形手术的医疗器械。该公司主要提供Motiva Implants品牌下的硅胶填充乳房植入物。它还提供Motiva Ergonomix和Motiva Ergonomix2重力敏感圆形软硅胶填充型乳房植入物;以及Motiva Flora组织扩张器,以及分销用于自体脂肪组织采集和再分配的纯移植物系列产品。
进一步阅读
- 免费获取StockNews.com关于机构实验室的研究报告(ESTA)
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
接受机构实验室每日的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对机构实验室和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧